Mortality in People with Type 2 Diabetes Following SARS-CoV-2 InfectionCitation formats

  • External authors:
  • Adrian H Heald
  • Richard Williams
  • Rajshekhar N Mudaliar
  • Asma Naseem
  • Kelly A Bowden Davies
  • Yonghong Peng
  • Simon G Anderson
  • Gayathri Delanerolle
  • J Martin Gibson

Standard

Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection : A Population Level Analysis of Potential Risk Factors. / Heald, Adrian H; Jenkins, David A; Williams, Richard; Sperrin, Matthew; Mudaliar, Rajshekhar N; Syed, Akheel; Naseem, Asma; Bowden Davies, Kelly A; Peng, Yonghong; Peek, Niels; Ollier, William; Anderson, Simon G; Delanerolle, Gayathri; Gibson, J Martin.

In: Diabetes Therapy, 13.04.2022.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Heald, Adrian H ; Jenkins, David A ; Williams, Richard ; Sperrin, Matthew ; Mudaliar, Rajshekhar N ; Syed, Akheel ; Naseem, Asma ; Bowden Davies, Kelly A ; Peng, Yonghong ; Peek, Niels ; Ollier, William ; Anderson, Simon G ; Delanerolle, Gayathri ; Gibson, J Martin. / Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection : A Population Level Analysis of Potential Risk Factors. In: Diabetes Therapy. 2022.

Bibtex

@article{8276d091b2a94aecaced04bafb65569f,
title = "Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors",
abstract = "INTRODUCTION: Research is ongoing to increase our understanding of how much a previous diagnosis of type 2 diabetes mellitus (T2DM) affects someone's risk of becoming seriously unwell following a COVID-19 infection. In this study we set out to determine the relative likelihood of death following COVID-19 infection in people with T2DM when compared to those without T2DM. This was conducted as an urban population study and based in the UK.METHODS: Analysis of electronic health record data was performed relating to people living in the Greater Manchester conurbation (population 2.82 million) who had a recorded diagnosis of T2DM and subsequent COVID-19 confirmed infection. Each individual with T2DM (n = 13,807) was matched with three COVID-19-infected non-diabetes controls (n = 39,583). Data were extracted from the Greater Manchester Care Record (GMCR) database for the period 1 January 2020 to 30 June 2021. Social disadvantage was assessed through Townsend scores. Death rates were compared in people with T2DM to their respective non-diabetes controls; potential predictive factors influencing the relative likelihood of admission were ascertained using univariable and multivariable logistic regression.RESULTS: For individuals with T2DM, their mortality rate after a COVID-19 positive test was 7.7% vs 6.0% in matched controls; the relative risk (RR) of death was 1.28. From univariate analysis performed within the group of individuals with T2DM, the likelihood of death following a COVID-19 recorded infection was lower in people taking metformin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 (GLP-1) agonist. Estimated glomerular filtration rate (eGFR) and hypertension were associated with increased mortality and had odds ratios of 0.96 (95% confidence interval 0.96-0.97) and 1.92 (95% confidence interval 1.68-2.20), respectively. Likelihood of death following a COVID-19 infection was also higher in those people with a diagnosis of chronic obstructive pulmonary disease (COPD) or severe enduring mental illness but not with asthma, and in people taking aspirin/clopidogrel/insulin. Smoking in people with T2DM significantly increased mortality rate (odds ratio of 1.46; 95% confidence interval 1.29-1.65). In a combined analysis of patients with T2DM and controls, multiple regression modelling indicated that the factors independently relating to a higher likelihood of death (accounting for 26% of variance) were T2DM, age, male gender and social deprivation (higher Townsend score).CONCLUSION: Following confirmed infection with COVID-19 a number of factors are associated with mortality in individuals with T2DM. Prescription of metformin, SGLT2is or GLP-1 agonists and non-smoking status appeared to be associated with a reduced the risk of death for people with T2DM. Age, male sex and social disadvantage are associated with an increased risk of death.",
author = "Heald, {Adrian H} and Jenkins, {David A} and Richard Williams and Matthew Sperrin and Mudaliar, {Rajshekhar N} and Akheel Syed and Asma Naseem and {Bowden Davies}, {Kelly A} and Yonghong Peng and Niels Peek and William Ollier and Anderson, {Simon G} and Gayathri Delanerolle and Gibson, {J Martin}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = apr,
day = "13",
doi = "10.1007/s13300-022-01259-3",
language = "English",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Nature",

}

RIS

TY - JOUR

T1 - Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection

T2 - A Population Level Analysis of Potential Risk Factors

AU - Heald, Adrian H

AU - Jenkins, David A

AU - Williams, Richard

AU - Sperrin, Matthew

AU - Mudaliar, Rajshekhar N

AU - Syed, Akheel

AU - Naseem, Asma

AU - Bowden Davies, Kelly A

AU - Peng, Yonghong

AU - Peek, Niels

AU - Ollier, William

AU - Anderson, Simon G

AU - Delanerolle, Gayathri

AU - Gibson, J Martin

N1 - © 2022. The Author(s).

PY - 2022/4/13

Y1 - 2022/4/13

N2 - INTRODUCTION: Research is ongoing to increase our understanding of how much a previous diagnosis of type 2 diabetes mellitus (T2DM) affects someone's risk of becoming seriously unwell following a COVID-19 infection. In this study we set out to determine the relative likelihood of death following COVID-19 infection in people with T2DM when compared to those without T2DM. This was conducted as an urban population study and based in the UK.METHODS: Analysis of electronic health record data was performed relating to people living in the Greater Manchester conurbation (population 2.82 million) who had a recorded diagnosis of T2DM and subsequent COVID-19 confirmed infection. Each individual with T2DM (n = 13,807) was matched with three COVID-19-infected non-diabetes controls (n = 39,583). Data were extracted from the Greater Manchester Care Record (GMCR) database for the period 1 January 2020 to 30 June 2021. Social disadvantage was assessed through Townsend scores. Death rates were compared in people with T2DM to their respective non-diabetes controls; potential predictive factors influencing the relative likelihood of admission were ascertained using univariable and multivariable logistic regression.RESULTS: For individuals with T2DM, their mortality rate after a COVID-19 positive test was 7.7% vs 6.0% in matched controls; the relative risk (RR) of death was 1.28. From univariate analysis performed within the group of individuals with T2DM, the likelihood of death following a COVID-19 recorded infection was lower in people taking metformin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 (GLP-1) agonist. Estimated glomerular filtration rate (eGFR) and hypertension were associated with increased mortality and had odds ratios of 0.96 (95% confidence interval 0.96-0.97) and 1.92 (95% confidence interval 1.68-2.20), respectively. Likelihood of death following a COVID-19 infection was also higher in those people with a diagnosis of chronic obstructive pulmonary disease (COPD) or severe enduring mental illness but not with asthma, and in people taking aspirin/clopidogrel/insulin. Smoking in people with T2DM significantly increased mortality rate (odds ratio of 1.46; 95% confidence interval 1.29-1.65). In a combined analysis of patients with T2DM and controls, multiple regression modelling indicated that the factors independently relating to a higher likelihood of death (accounting for 26% of variance) were T2DM, age, male gender and social deprivation (higher Townsend score).CONCLUSION: Following confirmed infection with COVID-19 a number of factors are associated with mortality in individuals with T2DM. Prescription of metformin, SGLT2is or GLP-1 agonists and non-smoking status appeared to be associated with a reduced the risk of death for people with T2DM. Age, male sex and social disadvantage are associated with an increased risk of death.

AB - INTRODUCTION: Research is ongoing to increase our understanding of how much a previous diagnosis of type 2 diabetes mellitus (T2DM) affects someone's risk of becoming seriously unwell following a COVID-19 infection. In this study we set out to determine the relative likelihood of death following COVID-19 infection in people with T2DM when compared to those without T2DM. This was conducted as an urban population study and based in the UK.METHODS: Analysis of electronic health record data was performed relating to people living in the Greater Manchester conurbation (population 2.82 million) who had a recorded diagnosis of T2DM and subsequent COVID-19 confirmed infection. Each individual with T2DM (n = 13,807) was matched with three COVID-19-infected non-diabetes controls (n = 39,583). Data were extracted from the Greater Manchester Care Record (GMCR) database for the period 1 January 2020 to 30 June 2021. Social disadvantage was assessed through Townsend scores. Death rates were compared in people with T2DM to their respective non-diabetes controls; potential predictive factors influencing the relative likelihood of admission were ascertained using univariable and multivariable logistic regression.RESULTS: For individuals with T2DM, their mortality rate after a COVID-19 positive test was 7.7% vs 6.0% in matched controls; the relative risk (RR) of death was 1.28. From univariate analysis performed within the group of individuals with T2DM, the likelihood of death following a COVID-19 recorded infection was lower in people taking metformin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 (GLP-1) agonist. Estimated glomerular filtration rate (eGFR) and hypertension were associated with increased mortality and had odds ratios of 0.96 (95% confidence interval 0.96-0.97) and 1.92 (95% confidence interval 1.68-2.20), respectively. Likelihood of death following a COVID-19 infection was also higher in those people with a diagnosis of chronic obstructive pulmonary disease (COPD) or severe enduring mental illness but not with asthma, and in people taking aspirin/clopidogrel/insulin. Smoking in people with T2DM significantly increased mortality rate (odds ratio of 1.46; 95% confidence interval 1.29-1.65). In a combined analysis of patients with T2DM and controls, multiple regression modelling indicated that the factors independently relating to a higher likelihood of death (accounting for 26% of variance) were T2DM, age, male gender and social deprivation (higher Townsend score).CONCLUSION: Following confirmed infection with COVID-19 a number of factors are associated with mortality in individuals with T2DM. Prescription of metformin, SGLT2is or GLP-1 agonists and non-smoking status appeared to be associated with a reduced the risk of death for people with T2DM. Age, male sex and social disadvantage are associated with an increased risk of death.

U2 - 10.1007/s13300-022-01259-3

DO - 10.1007/s13300-022-01259-3

M3 - Article

C2 - 35416588

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

ER -